Loading…
Bidirectional control of airway responsiveness by endogenous cannabinoids
Smoking marijuana or administration of its main active constituent, Δ 9-tetrahydrocannabinol (Δ9-THC), may exert potent dilating effects on human airways. But the physiological significance of this observation and its potential therapeutic value are obscured by the fact that some asthmatic patients...
Saved in:
Published in: | Nature (London) 2000-11, Vol.408 (6808), p.96-101 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Smoking marijuana or administration of its main active constituent, Δ
9-tetrahydrocannabinol (Δ9-THC), may exert potent
dilating effects on human airways. But the physiological
significance of this observation and its potential therapeutic value are obscured
by the fact that some asthmatic patients respond to these compounds with
a paradoxical bronchospasm. The mechanisms underlying these
contrasting responses remain unresolved. Here we show that the endogenous
cannabinoid anandamide exerts dual effects on bronchial responsiveness in
rodents: it strongly inhibits bronchospasm and cough evoked by the chemical
irritant, capsaicin, but causes bronchospasm when the constricting tone exerted
by the vagus nerve is removed. Both effects are mediated through peripheral
CB1 cannabinoid receptors found on axon terminals of airway nerves. Biochemical
analyses indicate that anandamide is synthesized in lung tissue on calcium-ion
stimulation, suggesting that locally generated anandamide participates in
the intrinsic control of airway responsiveness. In support of this conclusion,
the CB1 antagonist SR141716A enhances capsaicin-evoked bronchospasm and cough.
Our results may account for the contrasting bronchial actions of cannabis-like
drugs in humans, and provide a framework for the development of more selective
cannabinoid-based agents for the treatment of respiratory pathologies. |
---|---|
ISSN: | 0028-0836 1476-4687 |
DOI: | 10.1038/35040576 |